Introduction {#s1}
============

Gamma-glutamyltransferase(GGT) is a common biomarker of liver injury and alcohol consumption [@pone.0048878-Whitfield1]. However, recent epidemiologic and clinical studies have also found a close association between GGT level and risk of cardiovascular disease, diabetes, and metabolic syndrome [@pone.0048878-Nakanishi1], [@pone.0048878-Lee1], [@pone.0048878-Ryu1]. The relationships between them were further strengthened by published meta-analyses [@pone.0048878-Liu1], [@pone.0048878-Fraser1], [@pone.0048878-Fraser2].

In the past twenty years, the association between GGT and risk of hypertension has been deeply investigated in cross-sectional and longitudinal studies [@pone.0048878-Xu1]--[@pone.0048878-Miura1]. However, these studies drew inconsistent, even opposite conclusions. For example, Kim et al [@pone.0048878-Kim1] found a significant association between GGT quartiles and hypertension only in the drinkers and non-overweight subgroups, while Stranges et al [@pone.0048878-Stranges1] showed that higher GGT level increased the risk of hypertension in both noncurrent and current drinkers. Because of these inconsistent findings, we therefore conducted a systematic review and meta-analysis to attempt to solve the problem.

Methods {#s2}
=======

Search Strategy {#s2a}
---------------

The Pubmed, Embase, and Science Citation Index (ISI Web of Science) databases were searched to collect all publications on the association between GGT and hypertension (last search update: 15th June 2012) without language restriction. The following search terms were used: (Gamma-glutamyltransferase\[MeSH\] OR Gamma-glutamyltransferase\[All Fields\] OR gamma-GT\[All Fields\] OR GGT\[All Fields\] OR GGTP\[All Fields\]) AND (Hypertension\[MeSH\] OR Hypertension \[All Fields\] OR "Essential Hypertension"\[All Fields\] OR "Primary Hypertension"\[All Fields\] OR "High blood pressure"\[All Fields\]. Similar search terms were applied to Embase and the Science Citation Index. Moreover, reference lists were further retrieved from published articles to avoid missing any relevant studies. Our meta-analysis was performed according to the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines [@pone.0048878-Stroup1].

Study selection {#s2b}
---------------

Studies were included if they satisfied the following criteria: 1) the study design should be a prospective design; 2) GGT level in baseline was reported and hypertension as the outcome of interest; 3) the relative risk(RR) or odds ratio(OR) with 95% confidence intervals(CIs) were provided or obtained by calculation.

Data extraction {#s2c}
---------------

Two authors extracted information independently and disagreements were resolved by discussion and consensus. The following data were extracted from each included article: name of the first author, year of publication, country of origin, mean age of the populations, gender component, numbers of participants and cases, durations of follow-up, diagnostic criteria for ascertainment of hypertension, most fully adjusted effect estimates from multivariable for the highest versus the lowest group of GGT level with corresponding 95%CI and study-specific adjusted confounding factors. When the effect estimates of the same population were reported in different follow-up durations, we only included the data with the longest follow-up time.

Statistical analysis {#s2d}
--------------------

Relative risk (RR) and 95% CI were chosen as the effect estimate to assess the association between GGT and hypertension. We calculated the combined RR and 95%CI using the most-adjusted RRs(by comparing the highest versus lowest category of GGT level). Heterogeneity among studies was examined by using chi-square-based Q test and I^2^ test. When significant heterogeneity (P value\<0.05 and I^2^\>50%) was detected, the pooled RR and 95%CI would be estimated in a random-effect model. Otherwise, a fixed-effect model was chosen. Subgroup analyses were further carried out by race/ethnicity, sex, sample sizes, durations of follow-up, definition of hypertension and number of adjusted confounding factors. In addition, we also analyzed combined RR per 1 SD (standard deviation) logGGT increment in three studies which presented their results (RRs) in per 1 SD logGGT increment.

A sensitivity analysis was performed to evaluate whether the results were markedly affected by a single study. Publication bias was evaluated with Begg\'s and Egger\'s test, with a P value \>0.05 considered as no significant. All statistical analyses were conducted with Stata software, version 11.0 (Stata Corp, College Station, Texas, USA). A P value\<0.05 was considered statistically significant.

Results {#s3}
=======

Literature search {#s3a}
-----------------

The flow diagram of literature search was shown in [Figure 1](#pone-0048878-g001){ref-type="fig"}. 1469 potentially relevant articles were initially identified. Of the 1469 articles identified, 1443 papers were excluded based on titles and abstracts. The remaining 26 articles were then further evaluated by reviewing full text. 13 studies were excluded due to the following reasons: 7 studies not a prospective design, 2 studies repeated with included studies, and 4 studies focused on the change of GGT over time with blood pressure. Finally, 13 articles [@pone.0048878-Xu1]--[@pone.0048878-Miura1] were included in our meta-analysis.

![Flow diagram of included studies of meta-analysis.](pone.0048878.g001){#pone-0048878-g001}

Study characteristics {#s3b}
---------------------

Thirteen prospective cohort studies involving 43314 participants and 5280 cases of hypertension were included in our meta-analysis. The characteristics of the 13 articles were summarized in [Table 1](#pone-0048878-t001){ref-type="table"}. Among 13 studies, 10 studies were conducted in Asia, 2 in North-America, and 1 in Europe. The durations of follow-up ranged from 3 to 15 years. As to diagnosis of hypertension, hypertension was defined as blood pressure ≧160/95 mmHg, 140/90 mmHg, 130/85 mmHg and/or taking antihypertensive medications. Twelve studies including 15 data points (as 3 studies provided their results for men and women separately) offered the RRs and 95%CIs of highest versus lowest category of GGT level. Moreover, three studies [@pone.0048878-Onat1], [@pone.0048878-Cheung1], [@pone.0048878-Miura1] reporting their results in per 1 SD logGGT increment were exclusively analyzed.

10.1371/journal.pone.0048878.t001

###### Characteristics of studies included in meta-analysis.

![](pone.0048878.t001){#pone-0048878-t001-1}

  Study                                       Country   Case/Total \[age(y)\]   Gender M/F   Definition of Hypertension   Follow-up (years)   Comparison (Highest vs Lowest, U/L)              Adjusted RR(95%CI)                                                                                Adjustment for covariates
  ------------------------------------------ --------- ----------------------- ------------ ---------------------------- ------------------- -------------------------------------- ---------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Yamada [@pone.0048878-Yamada1]; 1991         Japan      29/1393 (35--54)        1393/0              ≧160/95                     5                       ≧50 vs \<50                           4.52(2.17--9.40)                                                                                            None
  Miura [@pone.0048878-Miura1], 1994           Japan       36/77 (30--69)          77/0            ≧140/90, meds                 10                       ≧20 vs \<10                          5.82(1.83--18.56)                                                                            Age, SBP, DBP, alcohol consumption.
                                                                                                                                                   Per 1 SD logGGT increment                    1.41(1.09--1.83)             
  Lee [@pone.0048878-Lee3], 2002               Korea      169/8170 (25--50)       8170/0           ≧160/95, meds                  4                        ≧50 vs ≦9                             1.5(0.8--2.8)                               Age, BMI, smoking, drinking, exercise, family history of hypertension, SBP or DBP, the change of BMI, drinking during four years.
  Lee [@pone.0048878-Lee2], 2003                USA       708/4704 (18--30)         NA             ≧140/90, meds                 15                       \>36 vs ≦12                            1.5(1.0--2.2)                                Age, sex, race, study center, BMI, alcohol consumption, cigarette smoking, physical activity, systolic blood pressure, insulin.
  Stranges [@pone.0048878-Stranges1], 2005      USA       195/897 (39--79)       587/310           ≧140/90, meds                  6                     (39--55) vs ≦14                          2.1(1.1--4.0)                                            Age, gender, race, average of alcohol, smoking status, BMI, physical activity, systolic blood pressure.
  Ander [@pone.0048878-Andre1], 2007          France        492/2273 (NA)       1129/1144          ≧130/85, meds                  3           M: ≧49.4 vs \<19.7; F: ≧23 vs \<12.6   M:1.76(1.06--2.92); F:1.38(0.87--2.20)                                                                                 Age
  Jo [@pone.0048878-Jo1], 2009                 Korea       2170/17281 (NA)      11659/5622         ≧130/85, meds                  4              M:\>38 vs \<19; F:\>15 vs \<9       M:2.44(2.07--2.88); F:1.49(1.14--1.94)                                                                                 Age
  Jimba [@pone.0048878-Jimba1], 2009           Japan       288/1027 (49±8)          NA             ≧130/85, meds                  3                        ≧42 vs ≦24                           1.15(0.76--1.73)                                                                                Age, sex, alcohol habit, BMI
  Hwang [@pone.0048878-Hwang1], 2010           Korea      83/293 (54.1±8.9)      115/176           ≧140/90, meds                  5             M: \>46 vs \<17; F: \>19 vs \<9        M:0.5(0.1--2.8); F:7.8((2.4--25.0)                            Age, education, BMI, alcohol intake, cigarette smoking, exercise, salt intake, family history of hypertension, ALT
  Cheung [@pone.0048878-Cheung1], 2011         China     126/708 (47.3±9.7)      428/280           ≧140/90, meds                 5.3              M: ≧31 vs ≦20; F: ≧20 vs ≦13                  2.68(1.36--5.26)              Age, sex, systolic blood pressure at baseline, follow-up duration, BMI, triglycerides, HDL cholesterol, HOMA-IR, CRP, fibrinogen, current smoking, change in BMI
                                                                                                                                                   Per 1 SD logGGT increment                    1.38(1.05--1.81)             
  Xu [@pone.0048878-Xu1], 2011                 China        119/285 (NA)            NA             ≧130/85, meds                 3.5                    (41--68) vs \<16                        1.55(0.72--3.31)                                                                                          Age, sex
  Onat [@pone.0048878-Onat1], 2012            Turkey      476/1423 (33--84)      735/678           ≧140/90, meds                  4                Per 1 SD logGGT increment                    1.20(1.10--1.31)                                                                          Age, sex, menopause, BMI, alcohol usage
  Kim [@pone.0048878-Kim1], 2012               Korea      389/4783 (44±5.8)     3246/1537          ≧140/90, meds                  3                    (29--51) vs ≦12.9                      2.638(1.259--5.528)                  Age, sex, alcohol amount, smoking status, physical activity, BMI, baseline glucose, uric acid, HDL, LDL, TG, Hs-CRP, baseline systolic blood pressure

Abbreviations: NA: not applicable; M, Man; F, Female; BMI, body mass index; ALT, alanine aminotransferase; HOMA-IR, homeostasis model assessment index of insulin resistance; CRP, C-reactive protein; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; TG, triglyceride.

Meta-analysis {#s3c}
-------------

As is shown in [Figure 2](#pone-0048878-g002){ref-type="fig"}, the pooled RR of hypertension was 1.94(95%CI: 1.55--2.43; P\<0.001) for the highest versus lowest category of GGT level; statistical heterogeneity was found in the study results (Q = 40.29, P = 0.000, I^2^ = 65.3%).

![Meta-analysis of risk of hypertension between highest vs lowest category of GGT.](pone.0048878.g002){#pone-0048878-g002}

As above, three studies [@pone.0048878-Onat1], [@pone.0048878-Cheung1], [@pone.0048878-Miura1] provided their results in per 1 SD logGGT increment. Overall, risk of hypertension increased by 23% (summary RR: 1.23; 95%CI: 1.13--1.32; P\<0.001) per 1 SD logGGT increments without evident heterogeneity (Q = 1.82, P = 0.403, I^2^ = 0%).

Subgroup and sensitivity analyses {#s3d}
---------------------------------

The effects of GGT level on risk of hypertension in different subgroups are shown in [Table 2](#pone-0048878-t002){ref-type="table"}. Overall, the positive association between GGT level and risk of hypertension was consistently observed in each subgroup except in ≧160/95 subgroup (RR: 2.56, 95%CI: 0.87--7.54; P = 0.088) and nondrinkers (RR: 1.76, 95%CI: 0.88--3.53; P = 0.113).

10.1371/journal.pone.0048878.t002

###### Subgroup analyses of GGT level and risk of hypertension.

![](pone.0048878.t002){#pone-0048878-t002-2}

  Group                        Number of studies      RR(95%CI)       P value for effect estimates   P value for heterogeneity   I^2^(%)
  --------------------------- ------------------- ------------------ ------------------------------ --------------------------- ---------
  All studies                         15a          1.94(1.55--2.44)             \<0.001                       \<0.001             65.3
  Race/ethnicity                                                                                                                
  Asians                              11           2.14(1.58--2.90)             \<0.001                       \<0.001             71.6
  Non-Asians                           4           1.59(1.25--2.03)             \<0.001                        0.727                0
  Gender                                                                                                                        
  Men only                             6           2.29(1.56--3.37)             \<0.001                        0.033              58.8
  Women only                           3           1.91(1.06--3.43)              0.031                         0.022              73.8
  Both men and women                   6           1.70(1.28--2.24)             \<0.001                        0.203              31.0
  Drinking status                                                                                                               
  Nondrinkers                          5           1.76(0.88--3.53)              0.113                         0.136              42.8
  Drinkers                             4           2.39(1.29--4.44)              0.006                         0.051              61.4
  Durations, y                                                                                                                  
  ≤5                                  11           1.87(1.42--2.45)             \<0.001                       \<0.001             70.8
  \>5                                  4           2.23(1.40--3.53)              0.001                         0.110              50.2
  Sample size                                                                                                                   
  ≤1000                                5           2.86(1.48--5.54)              0.002                         0.053              57.2
  \>1000                              10           1.77(1.39--2.24)             \<0.001                        0.001              67.8
  Definition of HBP                                                                                                             
  ≧160/95                              2           2.56(0.87--7.54)              0.088                         0.025              80.1
  ≧140/90,                             7           2.44(1.54--3.86)             \<0.001                        0.026              58.1
  \>130/85                             6           1.63(1.21--2.18)              0.001                         0.001              74.9
  Adjustment for covariates                                                                                                     
  ≤5 factors                           8           1.90(1.40--2.57)             \<0.001                       \<0.001             75.3
  \>5 factors                          7           2.05(1.40--3.00)             \<0.001                        0.066              49.2

a: twelve studies including 15 data points.

To evaluate the impact of single studies on the combined results, we conducted sensitivity analyses by omitting one study at a time and reassessed the summary RR for the remaining studies. As is shown in [Figure 3](#pone-0048878-g003){ref-type="fig"}, no single study significantly affects the pooled RRs

![Sensitivity analyses results of given named study omitted.](pone.0048878.g003){#pone-0048878-g003}

Publication bias {#s3e}
----------------

Begg\'s and Egger\'s test were performed to test if there was publication bias. As is shown in [Figure 4](#pone-0048878-g004){ref-type="fig"}, no publication bias was found (Egger\' test: P = 0.952)

![Begg\' funnel plot analysis of publication bias.](pone.0048878.g004){#pone-0048878-g004}

Discussion {#s4}
==========

Recent studies suggested that GGT was a novel biomarker of cardiovascular risk. As to the relationship between GGT and hypertension, previous studies have drawn inconsistent conclusions. In this study, we comprehensively evaluated the exact association between GGT level and risk of hypertension. Our present systematic review and meta-analysis of 13 prospective studies showed a significant positive association between GGT level and risk of hypertension (RR: 1.94, 95%CI: 1.55--2.43). Moreover, our results also showed that risk of hypertension increased by 23% (95%CI: 1.13--1.32) per 1 SD logGGT increment. Subgroup analyses showed that the positive association between GGT level and risk of hypertension consistently existed in each subgroup except in ≧160/95 subgroup (RR: 2.56, 95%CI: 0.87--7.54; P = 0.088) and nondrinkers subgroup (RR: 1.76, 95%CI: 0.88--3.53; P = 0.113).

In our subgroup analyses, an interesting phenomenon was observed: the positive association between GGT level and risk of hypertension was more significant in Asians and male subgroups than that in non-Asians and female subgroups. As is commonly known, Asians have more prevalence of hepatic diseases such as hepatitis B or C, while men are more prone to drink alcoholic beverages. Accordingly, subgroup analysis in nondrinkers showed an increased trend but did not reach a statistical significance (RR: 1.76, 95%CI: 0.88--3.53; P = 0.113). Therefore, although most studies in our meta-analysis have adjusted alcohol habits or liver diseases, the possibility that the positive association of GGT and risk of hypertension is explained by alcohol consumption or liver diseases is not completely excluded. However,three studies [@pone.0048878-Stranges1], [@pone.0048878-Kim1], [@pone.0048878-Hwang1] performed within normal range of GGT levels showed that relative risk is still much higher in highest category of normal range of GGT levels than that in lowest category (RR: 2.44, 95%CI: 1.15--5.20; P = 0.021). Hence, further prospective studies with much more strict inclusion criteria should be conducted to evaluate a more accurate relationship between GGT level and the development of hypertension.

Exact mechanisms that link GGT with hypertension are not fully elucidated, however, several possible explanations are as follows: Longitudinal study showed that GGT is positively associated with inflammation markers such as fibrinogen, C--reactive protein and F2-isoprostanes [@pone.0048878-Lee2]. In addition, a study found that GGT was expressed in human atherosclerotic lesions colocalizing with ox-LDL and foam cells, which could contribute to the progression of atherosclerosis [@pone.0048878-Franzini1]. Lastly, GGT plays an important role in the generation of free radical species through its interaction with iron [@pone.0048878-Lee4]. Base on the above findings, elevated GGT level could be a marker of inflammation condition and oxidative stress, which were important features of hypertension.

Several limitations in our study should be pointed out. First, although most included studies have adjusted for a series of potential confounders, the possibility of residual or unknown confounding still can not be completely excluded. Second, several studies included in our meta-analysis did not specifically exclude subjects with hepatic diseases or alcohol abuse at baseline, this may confuse the true association of GGT with hypertension as liver damage and alcohol intake could affect GGT levels. However, studies that investigated only in nondrinkers [@pone.0048878-Cheung1] or participants without hepatitis [@pone.0048878-Kim1] and within normal range of GGT levels [@pone.0048878-Stranges1], [@pone.0048878-Kim1], [@pone.0048878-Hwang1] also found a positive association between GGT level and risk of hypertension. Third, moderate heterogeneity was observed in our meta-analysis, which is not surprising because of methodological variations, including study population, different ranges of exposure, and number of adjustment factors among studies. To find out source of heterogeneity, we conducted a meta-regression analysis. Regrettably, we did not detect the source of heterogeneity (data not shown). Finally, publication bias may existed for studies with null results as these tend not to be published. However, we did not find evidence of publication bias in our meta-analysis.

In conclusion, our study suggests that GGT level is independently associated with the development of hypertension. However, further studies are needed to confirm our findings and elucidate the exact mechanisms between GGT and the incidence of hypertension.
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